TipRanks
Rohto Pharmaceutical Co Ltd (JP:4527)
:4527
Japanese Market
4527
Rohto Pharmaceutical Co
RESEARCH TOOLSreports
Want to see JP:4527 full AI Analyst Report?

Rohto Pharmaceutical Co (4527) Ratios

2 Followers

Rohto Pharmaceutical Co Ratios

JP:4527's free cash flow for Q2 2026 was ¥0.54. For the 2026 fiscal year, JP:4527's free cash flow was decreased by ¥ and operating cash flow was ¥0.11. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 26Mar 25Mar 24
Liquidity Ratios
Current Ratio
 ― 2.30 2.04 2.47 2.37
Quick Ratio
 ― 1.65 1.48 1.93 1.86
Cash Ratio
 ― 0.82 0.74 1.02 1.00
Solvency Ratio
 ― 0.29 0.31 0.40 0.36
Operating Cash Flow Ratio
 ― 0.39 0.41 0.39 0.39
Short-Term Operating Cash Flow Coverage
 ― 3.40 1.93 6.46 7.40
Net Current Asset Value
¥ ―¥ 67.45B¥ 73.68B¥ 115.62B¥ 95.64B
Leverage Ratios
Debt-to-Assets Ratio
 ― 0.15 0.12 0.03 0.04
Debt-to-Equity Ratio
 ― 0.24 0.20 0.04 0.06
Debt-to-Capital Ratio
 ― 0.19 0.17 0.04 0.05
Long-Term Debt-to-Capital Ratio
 ― 0.14 0.09 0.02 0.03
Financial Leverage Ratio
 ― 1.62 1.61 1.41 1.48
Debt Service Coverage Ratio
 ― 3.81 2.04 7.32 7.79
Interest Coverage Ratio
 ― 40.53 31.70 204.33 137.49
Debt to Market Cap
 ― 0.11 0.10 0.02 0.02
Interest Debt Per Share
 ― 272.96 272.29 46.86 52.34
Net Debt to EBITDA
 ― -0.28 -0.41 -1.56 -1.61
Profitability Margins
Gross Profit Margin
―54.91%53.23%58.07%57.58%
EBIT Margin
―14.02%14.00%15.40%14.47%
EBITDA Margin
―18.28%19.05%18.61%17.74%
Operating Profit Margin
―12.46%11.84%14.79%14.23%
Pretax Profit Margin
―13.72%13.62%15.33%14.37%
Net Profit Margin
―10.05%9.96%11.42%11.05%
Continuous Operations Profit Margin
―10.03%10.01%11.59%11.07%
Net Income Per EBT
―73.24%73.15%74.51%76.92%
EBT Per EBIT
―110.05%115.02%103.67%100.97%
Return on Assets (ROA)
―7.35%7.05%8.94%8.52%
Return on Equity (ROE)
―11.92%11.35%12.56%12.59%
Return on Capital Employed (ROCE)
―11.75%11.05%15.46%14.80%
Return on Invested Capital (ROIC)
―8.32%7.61%11.45%11.20%
Return on Tangible Assets
―8.48%8.52%9.18%8.79%
Earnings Yield
―6.09%6.30%4.51%4.17%
Efficiency Ratios
Receivables Turnover
 ― 4.42 4.47 3.92 3.93
Payables Turnover
 ― 6.31 7.10 5.38 5.41
Inventory Turnover
 ― 2.26 2.45 2.43 2.47
Fixed Asset Turnover
 ― 3.41 3.70 3.95 3.61
Asset Turnover
 ― 0.73 0.71 0.78 0.77
Working Capital Turnover Ratio
 ― 2.46 2.80 2.28 2.35
Cash Conversion Cycle
 ― 186.31 179.30 175.22 173.32
Days of Sales Outstanding
 ― 82.64 81.60 93.14 92.76
Days of Inventory Outstanding
 ― 161.52 149.11 149.97 148.04
Days of Payables Outstanding
 ― 57.85 51.41 67.90 67.48
Operating Cycle
 ― 244.16 230.71 243.11 240.80
Cash Flow Ratios
Operating Cash Flow Per Share
 ― 162.06 211.49 150.11 135.55
Free Cash Flow Per Share
 ― 122.20 160.62 111.04 92.12
CapEx Per Share
 ― 39.86 50.87 39.06 43.43
Free Cash Flow to Operating Cash Flow
 ― 0.75 0.76 0.74 0.68
Dividend Paid and CapEx Coverage Ratio
 ― 2.29 2.30 2.38 2.12
Capital Expenditure Coverage Ratio
 ― 4.07 4.16 3.84 3.12
Operating Cash Flow Coverage Ratio
 ― 0.60 0.79 3.26 2.64
Operating Cash Flow to Sales Ratio
 ― 0.12 0.14 0.13 0.13
Free Cash Flow Yield
―5.46%6.67%3.70%3.33%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― 16.43 15.88 22.15 23.96
Price-to-Sales (P/S) Ratio
 ― 1.65 1.58 2.53 2.65
Price-to-Book (P/B) Ratio
 ― 1.96 1.80 2.78 3.02
Price-to-Free Cash Flow (P/FCF) Ratio
 ― 18.30 14.99 27.05 30.07
Price-to-Operating Cash Flow Ratio
 ― 13.80 11.38 20.01 20.44
Price-to-Earnings Growth (PEG) Ratio
 ― 43.69 1.40 1.28 0.96
Price-to-Fair Value
 ― 1.96 1.80 2.78 3.02
Enterprise Value Multiple
 ― 8.75 7.90 12.04 13.31
Enterprise Value
 ― 493.56B 517.44B 606.61B 563.69B
EV to EBITDA
 ― 8.75 7.90 12.04 13.31
EV to Sales
 ― 1.60 1.51 2.24 2.36
EV to Free Cash Flow
 ― 17.73 14.26 23.95 26.82
EV to Operating Cash Flow
 ― 13.37 10.83 17.71 18.23
Tangible Book Value Per Share
 ― 945.43 1.05K 1.04K 900.83
Shareholders’ Equity Per Share
 ― 1.14K 1.34K 1.08K 918.60
Tax and Other Ratios
Effective Tax Rate
 ― 0.27 0.26 0.24 0.23
Revenue Per Share
 ― 1.35K 1.52K 1.19K 1.05K
Net Income Per Share
 ― 136.10 151.56 135.60 115.62
Tax Burden
 ― 0.73 0.73 0.75 0.77
Interest Burden
 ― 0.98 0.97 1.00 0.99
Research & Development to Revenue
 ― 0.05 0.04 0.04 0.05
SG&A to Revenue
 ― 0.38 0.37 0.17 0.18
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 1.19 1.40 1.11 0.90
Currency in JPY